Résumé
A recent in vitro study showed that pharmacological inhibition of the nuclear export receptor XPO1 suppresses oxaliplatin-induced nuclear release of HMGB1 and HMGB2, as well as the translocation of CALR to the plasma membrane. Moreover, cell-targeted-HMGB2 protein potently induced CALR exposure, even in the absence of oxaliplatin.
langue originale | Anglais |
---|---|
Numéro d'article | 2421028 |
journal | OncoImmunology |
Volume | 13 |
Numéro de publication | 1 |
Les DOIs |
|
état | Publié - 1 janv. 2024 |
Modification externe | Oui |